Pancreatic Cancer Gene Therapy: From Molecular Targets to Delivery Systems
AbstractThe continuous identification of molecular changes deregulating critical pathways in pancreatic tumor cells provides us with a large number of novel candidates to engineer gene-targeted approaches for pancreatic cancer treatment. Targets—both protein coding and non-coding—are being exploited in gene therapy to influence the deregulated pathways to facilitate cytotoxicity, enhance the immune response or sensitize to current treatments. Delivery vehicles based on viral or non-viral systems as well as cellular vectors with tumor homing characteristics are a critical part of the design of gene therapy strategies. The different behavior of tumoral versus non-tumoral cells inspires vector engineering with the generation of tumor selective products that can prevent potential toxic-associated effects. In the current review, a detailed analysis of the different targets, the delivery vectors, the preclinical approaches and a descriptive update on the conducted clinical trials are presented. Moreover, future possibilities in pancreatic cancer treatment by gene therapy strategies are discussed.
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Fillat, C.; Jose, A.; Bofill-De Ros, X.; Mato-Berciano, A.; Maliandi, M.V.; Sobrevals, L. Pancreatic Cancer Gene Therapy: From Molecular Targets to Delivery Systems. Cancers 2011, 3, 368-395.
Fillat C, Jose A, Bofill-De Ros X, Mato-Berciano A, Maliandi MV, Sobrevals L. Pancreatic Cancer Gene Therapy: From Molecular Targets to Delivery Systems. Cancers. 2011; 3(1):368-395.Chicago/Turabian Style
Fillat, Cristina; Jose, Anabel; Bofill-De Ros, Xavier; Mato-Berciano, Ana; Maliandi, Maria Victoria; Sobrevals, Luciano. 2011. "Pancreatic Cancer Gene Therapy: From Molecular Targets to Delivery Systems." Cancers 3, no. 1: 368-395.